Emerging Therapies for Previously Treated EGFR Wild-Type/Untested Non-Small-Cell Lung Cancer are Expected to Offer Efficacy Benefits Over Current Treatments - Beckley, Bluefield & Lewisburg News, Weather, Sports

Emerging Therapies for Previously Treated EGFR Wild-Type/Untested Non-Small-Cell Lung Cancer are Expected to Offer Efficacy Benefits Over Current Treatments

  • Local NewsLocal NewsMore>>

  • Woman suffers minor injuries after car rolls on I-77 in Raleigh County

    Woman suffers minor injuries after car rolls on I-77 in Raleigh County

    Wednesday, July 30 2014 10:13 PM EDT2014-07-31 02:13:55 GMT
    Car rolled multiple times on I-77 North in Raleigh County.Car rolled multiple times on I-77 North in Raleigh County.
    In Raleigh County, a woman is miraculously not seriously injured, after her car rolls over on I-77 around 6:30 Wednesday night.An eyewitness tells us the woman was driving in the left lane on the northbound side. She suddenly veered off the road, over corrected,then slammed into the side of a tractor trailer. The car rolled multiple times before coming to a stop on it's roof.The witness says two small dogs ran out of the car. Moments later, the woman crawled out and ran after one of the dogs....
    In Raleigh County, a woman is miraculously not seriously injured, after her car rolls over on I-77 around 6:30 Wednesday night.An eyewitness tells us the woman was driving in the left lane on the northbound side. She suddenly veered off the road, over corrected,then slammed into the side of a tractor trailer. The car rolled multiple times before coming to a stop on it's roof.The witness says two small dogs ran out of the car. Moments later, the woman crawled out and ran after one of the dogs....
  • UPDATE: Suspect in custody in connection with Montcalm shooting

    UPDATE: Suspect in custody in connection with Montcalm shooting

    Thursday, July 31 2014 7:16 PM EDT2014-07-31 23:16:53 GMT
     Emotions were high in Montcalm on Thursday following a shooting. Neighbors were not surprised to hear of the shooting in their area, because they say, violence is unfortunately all too common in their neighborhood.
    Emotions were high in Montcalm on Thursday following a shooting. Neighbors were not surprised to hear of the shooting in their area, because they say, violence is unfortunately all too common in their neighborhood.
  • Environmentalists talk about Mountain Top Removal as Coal Miners Protest in Pittsburgh

    Environmentalists talk about Mountain Top Removal as Coal Miners Protest in Pittsburgh

    Thursday, July 31 2014 6:59 PM EDT2014-07-31 22:59:03 GMT
    As hundreds of coal miners protest in Pittsburgh over the hearing on E-P-A regulations, 59News talks to an Environmental group to get both sides of the controversy."Coal River Mountain Watch" is a non-profit organization organization, out of Whitesville, Raleigh County.The organizations mission is to stop the destruction of our communities and environment by mountain top removal mining, to improve the quality of life in our area and to help rebuild sustainable communities.Mike Roselle a membe...
    As hundreds of coal miners protest in Pittsburgh over the hearing on E-P-A regulations, 59News talks to an Environmental group to get both sides of the controversy."Coal River Mountain Watch" is a non-profit organization organization, out of Whitesville, Raleigh County.The organizations mission is to stop the destruction of our communities and environment by mountain top removal mining, to improve the quality of life in our area and to help rebuild sustainable communities.Mike Roselle a membe...

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Decision Resources Group

Surveyed Payers Are Most Receptive to Therapies Offering a Median Overall Survival Benefit over Available Therapies, According to a New Report from Decision Resources Group

BURLINGTON, Mass., June 19, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, according to surveyed U.S. and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC). DRG also finds that improved median overall survival and increased progression-free survival are the greatest unmet needs in this indication. Surveyed oncologists express enthusiasm for PD-1 monoclonal antibody inhibitors and anticipate that Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab and Merck's pembrolizumab will demonstrate efficacy advantages over currently available therapies. Interviewed thought leaders also expressed enthusiasm for AstraZeneca's MEK inhibitor selumetinib in combination with docetaxel (generics) for the treatment of KRAS-mutant patients. 

Decision Resources Group Logo.

Other key findings from the DecisionBase report entitled Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested): Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival?: 

  • Payer perception: Improvements in overall survival are identified as an area of highest unmet need by surveyed oncologists, and surveyed payers indicate that emerging therapies that offer significant benefit in overall survival are highly desirable and would be readily reimbursed.
  • Clinical trial end points: Overall survival and progression-free survival have the most influence over surveyed U.S. and European oncologists' prescribing decisions for previously treated EGFR wild-type/untested NSCLC.
  • Emerging therapies: The treatment of NSCLC patients continues to evolve and is driven by the development of novel agents and, increasingly, therapies with associated biomarkers that are predictive of response (such as pembrolizumab and selumetinib). Surveyed payers regard the availability of a predictive biomarker as one of the key factors for granting favorable formulary status to novel therapies.
  • KRAS-mutant population: The need for more efficacious therapies to treat NSCLC patients who harbor KRAS mutations will be addressed to some extent by the approval of selumetinib. However, significant unmet need remains for this underserved patient population.

Comments from Decision Resources Group Analyst Kirsha Naicker, Ph.D., M.Sc.:

  • "Although improvement in median overall survival is associated with increases in physician preference share and prescribing likelihood, there appears to be a pricing threshold at which efficacy benefits no longer justify price premiums over current therapies."
  • "A therapy's toxicity profile is an important consideration for prescribing therapies for previously treated EGFR wild-type/untested NSCLC. Regardless, a therapy with a poor side effect profile that is highly efficacious and targets an area of high unmet need, such as selumetinib, is viewed favorably by physicians."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

©2012 PR Newswire. All Rights Reserved.